

Special Issue

Advances in Treatment of Gastroesophageal Cancer

Message from the Guest Editors

Treatment of gastroesophageal cancer has progressed dramatically during recent years. Immunotherapy is now a valid treatment option for microsatellite unstable (MSI high) or mismatch-repair-deficient (MMR-D) tumors and for those tumors that express high levels of PD-L1, measured using the combined positive score (CPS). For tumors that overexpress the HER2 protein, new drugs are now available, mainly novel antibody–drug conjugates (ADCs). Advances were also made in developing more efficient ways to administer intraperitoneal chemotherapy. PIPAC (pressurized intraperitoneal aerosol chemotherapy) is a groundbreaking method of delivering chemotherapy, enabling control of peritoneal metastasis with fewer adverse events compared with systemic chemotherapy. In this Special Issue, we welcome authors to submit papers on the recent advances in treatment of gastroesophageal cancer in terms of both systemic treatments and surgical approaches. **Keywords:** gastric cancer; esophageal cancer; immunotherapy; PIPAC; HER2

Guest Editors

Dr. Ofer Margalit

1. Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel
 2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
- Prof. Dr. Aviram Nissan

1. Department of General and Oncological Surgery-Surgery C, Sheba Medical Center, Tel-Hashomer, Israel
2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Deadline for manuscript submissions

closed (10 July 2023)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/139090

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/journal/

[jcm](https://jcm.mdpi.com/)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).